SCHEMBL26049047

SCHEMBL26049047

Cc1c(C)c(C)c(CNCCCCOCCNc2nc3cc(C(=O)O)ccc3c3cnccc23)c(C)c1C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 20/20 0.65
CSNK2A2 P19784 18/20 0.65
CSNK2B P67870 15/20 0.65
CSNK2A3 Q8NEV1 5/20 0.53
HDAC1 Q13547 4/20 0.53
HDAC6 Q9UBN7 1/20 0.53
CHEK1 O14757 1/20 0.47
GAK O14976 1/20 0.47
DAPK3 O43293 1/20 0.47
DYRK3 O43781 1/20 0.47
ULK1 O75385 1/20 0.47
STK10 O94804 1/20 0.47
CCNB2 O95067 1/20 0.47
CDK1 P06493 1/20 0.47
PIM1 P11309 1/20 0.47
CCNB1 P14635 1/20 0.47
PHKG2 P15735 1/20 0.47
CCNE1 P24864 1/20 0.47
CDK2 P24941 1/20 0.47
TYK2 P29597 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26049012 0.93 CSNK2A1 (0.56) CSNK2A1CSNK2A2CSNK2BCSNK2A3HDAC1
SCHEMBL26049075 0.86 CSNK2A2 (0.49) CSNK2A1CSNK2A2CSNK2B
SCHEMBL26048822 0.86 CSNK2A1 (0.74) CSNK2A1CSNK2A2CSNK2BCSNK2A3HDAC1
SCHEMBL26049043 0.86 CSNK2A1 (0.59) CSNK2A1CSNK2A2CSNK2BCSNK2A3HDAC1
SCHEMBL25370206 0.84 CSNK2A2 (0.73) CSNK2A1CSNK2A2CSNK2BCSNK2A3HDAC1
SCHEMBL30511647 0.84 CSNK2A2 (0.73) CSNK2A1CSNK2A2CSNK2BCSNK2A3HDAC1
SCHEMBL29900213 0.84 CSNK2A1 (0.62) CSNK2A1CSNK2A2CSNK2BCSNK2A3HDAC1
SCHEMBL25371832 0.84 CSNK2A1 (0.62) CSNK2A1CSNK2A2CSNK2BCSNK2A3HDAC1
SCHEMBL25370461 0.84 CSNK2A1 (0.71) CSNK2A1CSNK2A2CSNK2BCSNK2A3HDAC1
SCHEMBL25371982 0.84 CSNK2A1 (0.57) CSNK2A1CSNK2A2CSNK2BCSNK2A3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250097-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF Apollo Therapeutics Limited (GB) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250097-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CSNK1A1, CSNK1D, CSNK2A1 CSNK2A1 3/4885CSNK2A2 5/4885CSNK2B 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.